Drug Profile
Research programme: cancer therapy - Gemin X/Phytera
Alternative Names: Cancer therapy research programme - Gemin X/PhyteraLatest Information Update: 10 Aug 2007
Price :
$50
*
At a glance
- Originator Gemin X Biotechnologies; Phytera
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Apr 2003 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 02 Apr 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Jul 2001 Preclinical development for Cancer in Canada (unspecified route)